Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Alzheimer Disease 2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01584440
What this trial is testing

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Who this might be right for
AgitationAlzheimer's Disease
Avanir Pharmaceuticals 220
Early research (Phase 1)WithdrawnNCT02130661
What this trial is testing

Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers

Who this might be right for
Alzheimer's Disease
GlaxoSmithKline
Large-scale testing (Phase 3)Looking for participantsNCT06976203
What this trial is testing

Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Who this might be right for
Alzheimer's Disease
Bristol-Myers Squibb 586
Testing effectiveness (Phase 2)Study completedNCT03236792
What this trial is testing

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Who this might be right for
AL Amyloidosis
Icahn School of Medicine at Mount Sinai 28
Not applicableStudy completedNCT05837819
What this trial is testing

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2

Who this might be right for
Alzheimer's DiseaseSleep Disturbance
Icahn School of Medicine at Mount Sinai 135
Early research (Phase 1)Study completedNCT00757939
What this trial is testing

Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)

Who this might be right for
Alzheimer's Disease
Merck Sharp & Dohme LLC 40
Large-scale testing (Phase 3)Looking for participantsNCT05552157
What this trial is testing

Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Who this might be right for
Alzheimers DiseaseDementiaAlzheimers Disease, Familial
Washington University School of Medicine 280
Early research (Phase 1)Study completedNCT05408780
What this trial is testing

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

Who this might be right for
Alzheimer Disease
Cerecin 45
Testing effectiveness (Phase 2)Ended earlyNCT03702816
What this trial is testing

The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

Who this might be right for
Alzheimer DiseaseParkinson DiseaseInflammation
Aaron Ritter, MD 24
Not applicableStudy completedNCT01222351
What this trial is testing

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Who this might be right for
Late Onset Alzheimer Disease
New York State Psychiatric Institute 161
Early research (Phase 1)Ended earlyNCT01072812
What this trial is testing

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Who this might be right for
Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
Annovis Bio Inc. 5
Testing effectiveness (Phase 2)Looking for participantsNCT07589595
What this trial is testing

Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Who this might be right for
Cognitive DysfunctionLewy Body DiseaseSynucleinopathies+1 more
Eli Lilly and Company 350
Testing effectiveness (Phase 2)Ended earlyNCT06677203
What this trial is testing

Study of ASN51 in Adults With Early Alzheimer's Disease

Who this might be right for
Alzheimer Disease
Asceneuron S.A. 123
Not applicableLooking for participantsNCT07482072
What this trial is testing

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Who this might be right for
Alzheimer Dementia (AD)Diabete Type 2
Rigshospitalet, Denmark 60
Testing effectiveness (Phase 2)Study completedNCT01715350
What this trial is testing

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
VTBIO Co. LTD 151
Testing effectiveness (Phase 2)Study completedNCT00566397
What this trial is testing

Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Pfizer 402
Very early researchEnded earlyNCT02874820
What this trial is testing

I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD

Who this might be right for
Alzheimer Disease
Imperial College London 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT06691256
What this trial is testing

Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation

Who this might be right for
Alzheimer DiseaseDementiaMedication Adherence+1 more
HiDO Technologies 70
Testing effectiveness (Phase 2)Study completedNCT06745583
What this trial is testing

Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Who this might be right for
Mild, Moderate, or Severe Alzheimer's Disease
Elixiron Immunotherapeutics Inc. 7
Large-scale testing (Phase 3)Study completedNCT00253201
What this trial is testing

The Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Who this might be right for
Alzheimer DiseaseDementia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 636
Next Page